|
20 Dec 2024
|
Ion Exchange
|
Hem Securities
|
413.30
|
772.00
|
662.80
(-37.64%)
|
86.79 |
Buy
|
|
|
|
|
27 Mar 2024
|
Ion Exchange
|
AUM Capital
|
413.30
|
640.00
|
491.65
(-15.94%)
|
Target met |
Buy
|
|
|
|
|
03 Nov 2022
|
Ion Exchange
|
KamayaKya Wealth
|
413.30
|
2610.98
|
2234.90
(-81.51%)
|
Target met |
Buy
|
|
|
We estimate a 21% CAGR till FY24, driven by revenue recognition in major EPC projects, growth from the Chemical division and Consumable product division. We expect IEIL to post a PAT CAGR of ~22% during FY22-24E driven by EPC efficiencies and Chemical division margin improvement.
|
|
26 Sep 2022
|
Ion Exchange
|
Edelweiss
|
413.30
|
|
2005.25
(-79.39%)
|
Pre-Bonus/
Split |
Not Rated
|
|
|
All-round growth on the cards
|
|
07 Mar 2022
|
Ion Exchange
|
Hem Securities
|
413.30
|
2526.00
|
1821.40
(-77.31%)
|
Target met |
Buy
|
|
|
Co. posted decent set of numbers for the quarter ended 31st Dec 2021. During the Quarter, In Engineering division there is Improvement in order book, as order received from Numaligarh Refinery Limited, Also UP Jal Nigam project has commenced in this quarter, and Management is expecting higher revenue contribution in next few quarters....
|
|
26 Dec 2016
|
Ion Exchange
|
Ventura
|
413.30
|
539.00
|
278.60
(48.35%)
|
Target met |
Buy
|
|
|
Ion Exchange, despite having a tepid performance over the last few years, is up for exciting times. Execution of the Sri Lanka project is expected to take its revenue growth trajectory higher along with a hefty improvement in margins from the Engineering segment. The US FDA nod for pharma resins is a shot in the arm as it is expected to be the next lever of growth in the chemicals segment. As a result, we expect overall revenues to grow at a CAGR of 16% over FY16-19, from Rs 869.5 crores in FY16 to Rs 1,371 crores in FY19....
|